Role of three-dimensional echocardiography in breast cancer: Comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging

Journal of Clinical Oncology

Volumn 28, Issue 21, 2010, Pages 3429-3436

  Walker, Jonathan ^a   Bhullar, Navdeep ^a   Fallah Rad, Nazanin ^a   Lytwyn, Matthew ^a   Golian, Mehrdad ^a   Fang, Tielan ^a   Summers, Arthur R ^a   Singal, Pawan K ^a   Barac, Ivan ^a   Kirkpatrick, Iain D ^a   Jassal, Davinder S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIAC IMAGING; CARDIAC MAGNETIC RESONANCE IMAGING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FAMILY HISTORY; FEASIBILITY STUDY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MULTIPLE GATED ACQUISITION SCAN; PRIORITY JOURNAL; REPRODUCIBILITY; SINUS RHYTHM; SMOKING; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY; AGED; BREAST TUMOR; COMPARATIVE STUDY; ECHOCARDIOGRAPHY; ECHOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; STATISTICAL MODEL;

ADULT; AGED; BREAST NEOPLASMS; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, THREE-DIMENSIONAL; FEMALE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 77955294878     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.7294     Document Type: Article

References (51)

1. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998 (Pubitemid 28446849)
2. Lefrak EA, Pitha J, Rosenheim S, et al: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314, 1973
3. Keefe DL: Anthracycline-induced cardiomyopathy. Semin Oncol 28:2-7, 2001
4. Ng R, Green MD: Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opin Drug Saf 6:315-321, 2007 (Pubitemid 46767637)
5. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285-4289, 1992
6. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002 (Pubitemid 34111379)
7. Olin JJ, Muss HB: New strategies for managing metastatic breast cancer. Oncology (Williston Park) 14:629-641, 2000; discussion 642-644, 647-648, 2000
8. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
9. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
10. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
11. Jahanzeb M: Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 8:324-333, 2008
12. Rayson D, Richel D, Chia S, et al: Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: Current experience and future strategies. Ann Oncol 19:1530-1539, 2008
13. Ewer SM, Ewer MS: Cardiotoxicity profile of trastuzumab. Drug Saf 31:459-467, 2008 (Pubitemid 351695459)
14. Guarneri V, Frassoldati A, Bruzzi P, et al: Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 8:453-456, 2008
15. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
16. Yaal-Hahoshen N, Safra T: Herceptin (trastuzumab): Adjuvant and neoadjuvant trials. Isr Med Assoc J 8:416-421, 2006 (Pubitemid 43986056)
17. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
18. Wadhwa D, Fallah-Rad N, Grenier D, et al: Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A retrospective study. Breast Cancer Res Treat 117:357-364, 2009
19. McArthur HL, Barnett J, Chia S: A population-based study of trastuzumab-mediated cardiotoxicity among early stage breast cancer patients treated with adjuvant trastuzumab. J Clin Oncol 24:579s, 2006 (abstr 10640)
20. Ewer MS, Vooletich MT, Durand JB, et al: Reversibility of trastuzumab- related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-7826, 2005 (Pubitemid 46657379)
21. Nousiainen T, Vanninen E, Jantunen E, et al: Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy. J Intern Med 249:297-303, 2001 (Pubitemid 34293776)
22. Alexander J, Dainiak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278-283, 1979 (Pubitemid 9115687)
23. Villani F, Meazza R, Materazzo C: Noninvasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: Comparison with echocardiography. Anticancer Res 26:797-801, 2006 (Pubitemid 43206051)
24. Ganz WI, Sridhar KS, Ganz SS, et al: Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 53:461-470, 1996 (Pubitemid 26388387)
25. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, et al: Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 25:237-247, 1999 (Pubitemid 29417681)
26. Rajappan K, Bellenger NG, Anderson L, et al: The role of cardiovascular magnetic resonance in heart failure. Eur J Heart Fail 2:241-252, 2000 (Pubitemid 30670721)
27. Altena R, Perik PJ, van Veldhuisen DJ, et al: Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncol 10:391-399, 2009
28. Jacobs LD, Salgo IS, Goonewardena S, et al: Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J 27:460-468, 2006 (Pubitemid 43209172)
29. Takuma S, Ota T, Muro T, et al: Assessment of left ventricular function by real-time 3-dimensional echocardiography compared with conventional noninvasive methods. J Am Soc Echocardiogr 14:275-284, 2001 (Pubitemid 33095693)
30. Bicudo LS, Tsutsui JM, Shiozaki A, et al: Value of real time three-dimensional echocardiography in patients with hypertrophic cardiomyopathy: Comparison with two-dimensional echocardiography and magnetic resonance imaging. Echocardiography 25:717-726, 2008
31. Lang RM, Mor-Avi V, Sugeng L, et al: Threedimensional echocardiography: The benefits of the additional dimension. J Am Coll Cardiol 48:2053-2069, 2006 (Pubitemid 44738445)
32. Bellenger NG, Burgess MI, Ray SG, et al: Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 21:1387-1396, 2000
33. Bu L, Munns S, Zhang H, et al: Rapid full volume data acquisition by real-time 3-dimensional echocardiography for assessment of left ventricular indexes in children: A validation study compared with magnetic resonance imaging. J Am Soc Echocardiogr 18:299-305, 2005 (Pubitemid 40470392)
34. Gutiérrez-Chico JL, Zamorano JL, Pérez de Isla L, et al: Comparison of left ventricular volumes and ejection fractions measured by three-dimensional echocardiography versus by two-dimensional echocardiography and cardiac magnetic resonance in patients with various cardiomyopathies. Am J Cardiol 95:809-813, 2005
35. Kühl HP, Schreckenberg M, Rulands D, et al: High-resolution transthoracic real-time three-dimensional echocardiography: Quantitation of cardiac volumes and function using semi-automatic border detection and comparison with cardiac magnetic resonance imaging. J Am Coll Cardiol 43:2083-2090, 2004 (Pubitemid 38686806)
36. Pouleur AC, le Polain de Waroux JB, Pasquet A, et al: Assessment of left ventricular mass and volumes by three-dimensional echocardiography in patients with or without wall motion abnormalities: Comparison against cine magnetic resonance imaging. Heart 94:1050-1057, 2008 (Pubitemid 352039890)
37. van den Bosch AE, Robbers-Visser D, Krenning BJ, et al: Real-time transthoracic three-dimensional echocardiographic assessment of left ventricular volume and ejection fraction in congenital heart disease. J Am Soc Echocardiogr 19:1-6, 2006 (Pubitemid 43105352)
38. Zeidan Z, Erbel R, Barkhausen J, et al: Analysis of global systolic and diastolic left ventricular performance using volume-time curves by real-time three-dimensional echocardiography. J Am Soc Echocardiogr 16:29-37, 2003 (Pubitemid 36522814)
39. Schmidt MA, Ohazama CJ, Agyeman KO, et al: Real-time three-dimensional echocardiography for measurement of left ventricular volumes. Am J Cardiol 84:1434-1439, 1999
40. Anwar AM, Nosir YF: Role of real time three-dimensional echocardiography in heart failure. Echocardiography 25:983-992, 2008
41. Corbett JR, Akinboboye OO, Bacharach SL, et al: Equilibrium radionuclide angiocardiography. J Nucl Cardiol 13:e56-79, 2006
42. Lang RM, Bierig M, Devereux RB, et al: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463, 2005 (Pubitemid 41821197)
43. Soliman OI, Krenning BJ, Geleijnse ML, et al: A comparison between QLAB and TomTec full volume reconstruction for real time three-dimensional echocardiographic quantification of left ventricular volumes. Echocardiography 24:967-974, 2007 (Pubitemid 47485652)
44. Friedrich MG, Sechtem U, Schulz-Menger J, et al: Cardiovascular magnetic resonance in myocarditis: A JACC white paper. J Am Coll Cardiol 53:1475-1487, 2009
45. Kramer CM, Barkhausen J, Flamm SD, et al: Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: Board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 10:35, 2008
46. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310, 1986 (Pubitemid 16134762)
47. Corapçioglu F, Sarper N, Berk F, et al: Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: A comparative study with echocardiography and multigated radionuclide angiography. Pediatr Hematol Oncol 23:71-80, 2006 (Pubitemid 41769977)
48. Jenkins C, Bricknell K, Hanekom L, et al: Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol 44:878-886, 2004 (Pubitemid 39099588)
49. Strohm O, Schultz-Menger J, Pilz B, et al: Measurement of left ventricular dimensions and function in patients with dilated cardiomyopathy. J Magn Reson Imaging 13:367-371, 2001 (Pubitemid 32173402)
50. Grothues F, Smith GX, Moon JC, et al: Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90:29-34, 2002 (Pubitemid 34671198)
51. Fallah-Rad N, Lytwyn M, Fang T, et al: Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 10:5, 2008